Nature Reviews Drug Discovery

@NatRevDrugDisc · London · joined 28 Apr 2009

Editorial team of Nature Reviews Drug Discovery.

44 942Followers

469Following

4 172Posts total

27KViews on collected posts

Últimas publicaciones

Nature Reviews Drug Discovery@NatRevDrugDisc4 Sep

The FDA recently approved the first orexin receptor agonist for narcolepsy https://t.co/xrqJVAIRDr Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience ht 2.8K views · 32 likes · 6 reposts · 1 replies Open on X →

Nature Reviews Drug Discovery@NatRevDrugDisc3 Sep

@NatRevDrugDisc @iu22ie33 And the explanation. 451 views · 0 likes · 0 reposts · 0 replies Open on X →

Nature Reviews Drug Discovery@NatRevDrugDisc3 Sep

For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive review https://t.co/RNbKBGRrgm https://t.co/b3JOpR4MI7 9.1K views · 167 likes · 49 reposts · 1 replies Open on X →

Nature Reviews Drug Discovery@NatRevDrugDisc2 Sep

Solute carrier membrane transporters: emerging targets in CNS disorders https://t.co/0RpeFcducw https://t.co/YZV9hQkg2I This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy https://t.co/fFE3YiKZy8 2.9K views · 40 likes · 12 reposts · 1 replies Open on X →

Nature Reviews Drug Discovery@NatRevDrugDisc1 Sep

For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway https://t.co/mRjeD1BGoN https://t.co/b3NdcHcPJc https 9.7K views · 167 likes · 50 reposts · 0 replies Open on X →

Nature Reviews Drug Discovery@NatRevDrugDisc28 Aug

Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here https://t.co/kWQJeeYbZr https://t.co/AhUat2jkMB 2.1K views · 24 likes · 7 reposts · 0 replies Open on X →

Frente a cuentas del mismo tamaño

6 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. llega a más gente que cuentas de su tamaño.

Visualizaciones medianas2 840esta cuenta924mediana de 10K–100K

Alcance, %6.32%esta cuenta3.62%mediana de 10K–100K

Interacción, %1.66%esta cuenta1.52%mediana de 10K–100K

Métrica	Esta cuenta	Mediana de 10K–100K	Proporción
Visualizaciones medianas por publicación	2 840	924	3.07×
Alcance (visualizaciones ÷ seguidores)	6.32%	3.62%	1.75×
Tasa de interacción	1.66%	1.52%	1.09×

Otras cuentas de este rango → Comparar con otra cuenta → Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.1K28 Aug

9.7K1 Sep

2.9K2 Sep

9.1K3 Sep

451

2.8K4 Sep

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.47%28 Aug

2.25%1 Sep

1.84%2 Sep

2.38%3 Sep

0.00%

1.39%4 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes57.8%430 in total

Reposts16.7%124 in total

Replies0.4%3 in total

Quotes0.1%1 in total

Bookmarks25.0%186 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.